<DOC>
	<DOC>NCT00831922</DOC>
	<brief_summary>The objective of this study is to evaluate the activity of 2 oral doses of AB1010 in subjects suffering from active RA who have shown an inadequate response to one DMARD including MTX or anti-TNF, after 3 months (12 weeks) of treatment. The safety and efficacy will be evaluated on: Rate of patients achieving ACR 20, 50, 70 and 90 DAS (disease activity score) after 3 months treatment ACRn after 3 months treatment Therapeutic maintenance of AB1010 at 3 months Quality of Life assessed by SF12 Health Assessment Questionnaire (HAQ) Clinical and biological safety Pharmacokinetic profile of AB1010</brief_summary>
	<brief_title>Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>1. Meet American College of Rheumatology (ACR) criteria for RA 2. Have active RA 3. ACR functional class IIII 4. Disease onset at &gt; 16 years of age 5. Disease duration of at least 6 months 6. Failure to one DMARD including methotrexate and antiTNF alpha 1. Pregnant or breastfeeding women 2. Inadequate bone marrow function 3. Current use of a DMARD within 4 weeks (or 5 halflives, whichever is longer) of screening except for leflunomide which requires a specific washout 4. Any previous use of recombinant IL1Ra 5. Current use of more than 1 non steroidal antiinflammatory drug (NSAID) or change of dose of the NSAID within 4 weeks of baseline or NSAID use greater than the maximum recommended dose 6. Within 4 weeks before baseline, use of more than 10 mg/day of prednisone or equivalent or change in the dose of prednisone or equivalent, or having intraarticular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids (&gt;20 mg prednisone or equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>DMARD failure</keyword>
	<keyword>ACR</keyword>
</DOC>